Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.72 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.63 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.63 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.63 |
| ▸ | RXRA | P19793 | 1/20 | 0.60 |
| ▸ | RXRB | P28702 | 1/20 | 0.60 |
| ▸ | RXRG | P48443 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | CFD | P00746 | 1/20 | 0.55 |
| ▸ | PPIA | P62937 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9526423 | 0.86 | PTGER1 (0.72) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL20848378 | 0.85 | MRGPRX4 (0.54) | PTGER1PTGER4PTGER3PTGER2CYP2C9 | |
| SCHEMBL5096132 | 0.84 | PTGER1 (1.00) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL5227439 | 0.83 | RXRA (0.59) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL14720858 | 0.80 | PARP10 (0.60) | PTGER1MCL1PARP10 | |
| SCHEMBL4320064 | 0.79 | PTGER1 (0.55) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL2575349 | 0.79 | PTGER1 (0.49) | PTGER1CYP2C9CFDPPIAPARP10 | |
| SCHEMBL3861503 | 0.79 | KAT6A (0.56) | PARP1 | |
| SCHEMBL3789362 | 0.79 | PTGER1 (0.59) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL26160118 | 0.78 | MAOB (0.52) | PTGER1CYP2C9CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. | 2012-10-18 | — | — | US | disclosed |
| EP-2486002-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011042217-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | CBR1, CNR1, CBR3 | PTGER1 1191/4885PTGER4 3511/4885PTGER3 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.